...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in bioscience: a journal and virtual library >Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
【24h】

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

机译：树突状细胞疫苗而非特异型KLH蛋白疫苗可引发针对多发性骨髓瘤的治疗性肿瘤特异性免疫力。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Idiotype protein (Id) secreted by myeloma cells is the best-characterized tumor-specific antigen and is widely used in clinical trials of immunotherapy in B-cell tumors. In this study, we used a myeloma murine model to compare the efficacy of two commonly used vaccines in human trials, Id-keyhole limpet hemocyanin (KLH) protein versus Id-KLH-pulsed DC vaccines in preventing or treating myeloma and priming tumor-specific immune responses. Although both vaccines were able to protect mice from developing myeloma, only the DC vaccine induced therapeutic immunity in tumor-bearing mice. DC vaccinations not only retarded tumor growth but also eradicated established myeloma in 60% of mice. The therapeutic efficacy of the DC vaccine was associated with increased tumor-specific IFN-g and IL-4 T-cell responses and cytolytic activity of splenic T cells. Moreover, the vaccines induced tumor-specific immune responses that protected surviving mice from tumor rechallenge. Thus, our results demonstrate that Id-based DCvaccine but not Id-KLH protein vaccine can be therapeutic to established myeloma. Further studies are needed to optimize methods of DC-based vaccines to improve the efficacy of clinical trials.
机译：骨髓瘤细胞分泌的独特型蛋白（Id）是特征最明确的肿瘤特异性抗原，被广泛用于B细胞肿瘤免疫疗法的临床试验中。在这项研究中，我们使用了骨髓瘤鼠模型来比较两种在人体试验中常用的疫苗，Id-钥匙孔血蓝蛋白（KLH）蛋白与Id-KLH脉冲DC疫苗在预防或治疗骨髓瘤和引发肿瘤特异性中的功效免疫反应。尽管两种疫苗都能够保护小鼠免于发生骨髓瘤，但是只有DC疫苗才能在荷瘤小鼠中诱导治疗性免疫。 DC疫苗接种不仅延缓了肿瘤的生长，而且根除了60％小鼠中已建立的骨髓瘤。 DC疫苗的治疗功效与增加的肿瘤特异性IFN-g和IL-4 T细胞反应以及脾T细胞的细胞溶解活性有关。而且，疫苗诱导了肿瘤特异性免疫反应，从而保护了存活的小鼠免受肿瘤再攻击。因此，我们的结果表明，基于Id的DCvaccine而非Id-KLH蛋白疫苗可以治疗已建立的骨髓瘤。需要进一步的研究来优化基于DC的疫苗的方法，以提高临床试验的效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号